217 related articles for article (PubMed ID: 26156055)
1. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
3. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
5. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
6. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
7. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
8. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
11. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
12. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
13. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
[TBL] [Abstract][Full Text] [Related]
14. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
Fujio S; Hanaya R
No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
[TBL] [Abstract][Full Text] [Related]
15. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
17. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
[TBL] [Abstract][Full Text] [Related]
18. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
[TBL] [Abstract][Full Text] [Related]
19. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in the medical management of craniopharyngioma.
Iglesias P
Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
